JOURNAL OF VIROLOGY, June 2011, p. 5664 5668 Vol. 85, No. 11 0022-538X/11/$12.00 doi:10.1128/jvi.00232-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. NOTES The Naturally Attenuated Kunjin Strain of West Nile Virus Shows Enhanced Sensitivity to the Host Type I Interferon Response Stephane Daffis, 1 Helen M. Lazear, 1 Wen Jun Liu, 4 Michelle Audsley, 4 Michael Engle, 1 Alexander A. Khromykh, 4 * and Michael S. Diamond 1,2,3 * Departments of Medicine, 1 Molecular Microbiology, 2 and Pathology & Immunology, 3 Washington University School of Medicine, St. Louis, Missouri 63110, and Australian Infectious Disease Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD 4072, Australia 4 Received 1 February 2011/Accepted 9 March 2011 The host determinants that contribute to attenuation of the naturally occurring nonpathogenic strain of West Nile virus (WNV), the Kunjin strain (WNV KUN ), remain unknown. Here, we show that compared to a highly pathogenic North American strain, WNV KUN exhibited an enhanced sensitivity to the antiviral effects of type I interferon. Our studies establish that the virulence of WNV KUN can be restored in cells and mice deficient in specific interferon regulatory factors (IRFs) or the common type I interferon receptor. Thus, WNV KUN is attenuated primarily through its enhanced restriction by type I interferon- and IRF-3-dependent mechanisms. West Nile Virus (WNV) is a positive-stranded RNA mosquito-borne virus in the Flaviviridae family and is responsible for sporadic outbreaks of encephalitis in humans worldwide (20). A highly pathogenic North American strain of WNV (WNV NY99 ) has emerged and has caused over 30,000 diagnosed human cases, including more than 1,000 deaths over the past decade (http://www.cdc.gov/ncidod/dvbid/westnile/index.htm). In contrast to WNV NY99, the indigenous Australian strain of WNV, the Kunjin strain (WNV KUN ), has limited pathogenic capacity, as only 18 nonfatal cases in humans have been reported since its discovery almost 50 years ago (10). Genomic sequence comparisons between WNV NY99 and WNV KUN reveal a close relationship, with 97.7% identity at the amino acid level and only 33 of 77 substitutions being nonconservative (references 14 and 23; M. Audsley and A. Khromykh, unpublished results). Although differences in structural protein N-linked glycosylation have been postulated to explain, in part, the lack of pathogenicity of WNV KUN (3, 22), no study has definitively described the mechanism of natural attenuation. * Corresponding author. Mailing address for Michael S. Diamond: Departments of Medicine, Molecular Microbiology and Pathology & Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8051, St. Louis. Missouri 63110. Phone: (314) 362-2842. Fax: (314) 362-9230. E-mail: diamond@borcim.wustl.edu. Mailing address for Alexander A. Khromykh: Centre for Infectious Disease Research, School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia. Phone: 617-3346-7219. Fax: 617-3365-4620. E-mail: a.khromykh@uq.edu.au. Present address: Queensland University of Technology, Brisbane, QLD, Australia. Present address: Monash University, Melbourne, VIC, Australia. Published ahead of print on 16 March 2011. The pathogenesis of WNV is greatly influenced by the type I interferon (IFN) host response (7, 12, 21). While both WNV NY99 and WNV KUN can antagonize this response in vitro (reviewed in reference 8), WNV KUN is strongly attenuated in adult mice (2) and virulent only in very young mice, for which the host immune response to viruses has not fully matured. Although the less virulent phenotype of WNV KUN could be attributed to several factors, including its slightly delayed replication kinetics in C6/36 insect cells or Vero cells (data not shown), we hypothesized that the major part of its attenuation could be explained by its distinct interaction with the type I IFN response. Prior experiments showed that both WNV NY99 and WNV KUN could limit the type I IFN response by blocking the phosphorylation of STAT1 and STAT2 in cells (18). To define whether attenuation of WNV KUN was linked to a reduced capacity to replicate after the induction of an IFN response, human A549 cells were treated with increasing amounts of human alpha IFN (IFN- ; 10 0 to 10 4 IU/ml) 6 h prior to or 3 h after infection with WNV KUN or WNV NY99 generated from infectious cdna clones (13) at a multiplicity of infection (MOI) of 1. Viral production was measured 24 h after infection by a plaque assay using BHK21-15 cells. Pretreatment with 10 0 to 10 4 IU/ml of IFN- decreased the yield of WNV KUN 5- to 1,000-fold; in comparison, the same concentration of IFN- reduced the infectivity of WNV NY99 only 1- to 50-fold (P 0.05) in these cells (Fig. 1A, left panel). Similarly, treatment with 10 0 to 10 4 IU/ml of IFN- 3 h after infection reduced WNV KUN titers 10- to 100-fold compared to 1- to 10-fold for WNV NY99 (P 0.05) (Fig. 1A, right panel). Thus, WNV KUN exhibited enhanced sensitivity to IFN- compared to WNV NY99 regardless of whether it was added before or after infection. Since the inhibition of IFN signaling by WNV NY99 and 5664
VOL. 85, 2011 NOTES 5665 FIG. 1. WNV KUN antagonizes IFN- antiviral effects less efficiently than WNV NY99. (A) Effects of pre- or posttreatment of IFN- on WNV production. A549 cells were treated with the indicated doses of IFN- 6 h before (left panel) or 3 h after (right panel) infection with WNV KUN or WNV NY99, and virus production was evaluated at 24 h by plaque assay. (B) WNV KUN prevents IFN- -dependent nuclear translocation of STAT1 less efficiently than WNV NY99. A549 cells were infected with WNV KUN or WNV NY99 for 48 h, treated with IFN- for 30 min, fixed, permeabilized, and stained with anti-wnv E and -STAT1 antibodies. DAPI, 4,6 -diamidino-2-phenylindole. (C) WNV KUN prevents IFN- -dependent phosphorylation of STAT1 less efficiently than WNV NY99. A549 cells were infected with WNV KUN or WNV NY99 for 48 h, treated with IFN- for 30 min, and lysed. Levels of phosphorylated STAT1 (P-STAT1), STAT1, WNV E, and actin were examined by immunoblot analysis. WNV KUN is mediated, in part, through the blockade of STAT1 and STAT2 activation, we hypothesized that the enhanced sensitivity to IFN- may be due to a decreased capacity of WNV KUN to antagonize the IFN response by inhibiting these proteins. To evaluate this, A549 cells were infected with WNV KUN or WNV NY99 for 48 h and treated with 5,000 IU/ml of IFN- for 30 min, and the levels of activated nuclear and phosphorylated STAT1 were assessed by an immunofluorescence assay (IFA) or by immunoblotting. In WNV NY99 -infected cells, nuclear localization of STAT1, in response to IFN- treatment, was not detected by IFA, confirming that WNV NY99 efficiently antagonized IFN- signaling. In contrast, in WNV KUN -infected cells, the percentage of infected cells FIG. 2. Survival of mice infected with WNV KUN or WNV NY99. Eight- to 10-week-old wild-type and congenic deficient C57BL/6 mice were inoculated with 10 3 PFU of WNV KUN or WNV NY99 by footpad injection and monitored for mortality for 21 days. (A) Survival data with IRF-3 /, IRF-7 /, IRF-3 / IRF-7 /, or IFN- R / mice infected with WNV NY99 were statistically different (P 0.05) compared to those for the wild-type controls. (B) Survival data with IRF- 7 /, IRF-3 / IRF-7 /, and IFN- R / mice infected with WNV KUN were statistically different (P 0.05) compared to those for the wild-type controls. Kaplan-Meier survival curves were analyzed by the log- rank test. with nuclear STAT1 was appreciably higher (Fig. 1B). Correspondingly, the level of phosphorylated STAT1 in WNV KUN - infected cells after IFN- treatment was greater than that observed for WNV NY99 -infected cells (Fig. 1C). Thus, in A549 cells, WNV KUN has an increased sensitivity to the antiviral effects of IFN- compared to that of WNV NY99, due in part to a reduced relative capacity to block STAT1 phosphorylation and nuclear translocation. Since WNV KUN attenuation correlated with an enhanced sensitivity to IFN- in vitro, we questioned whether the absence of host factors involved in IFN induction or signaling would restore WNV KUN pathogenesis in vivo. To evaluate this, 8- to 10-week-old wild-type, interferon regulatory factor 3 knockout (IRF-3 / ), IRF-7 /, IRF-3 / IRF-7 / double-knockout, and IFN- / receptor knockout (IFN- R / )
5666 NOTES J. VIROL. FIG. 3. Viral burden in peripheral and central nervous system (CNS) tissues from mice infected with WNV KUN or WNV NY99. WNV RNA in serum (A to D) and infectious WNV virus in the spleen (E to H) and brain (I to L) were determined from samples harvested on the indicated days using quantitative reverse transcription-pcr (qrt-pcr; serum) or viral plaque assay (spleen and brain). Data are shown as viral RNA equivalents or PFU per gram of tissue for 5 to 10 mice per time point. The error bars indicate standard error of the mean, and the dotted line represents the limit of sensitivity of the assay. Asterisks ( *, P 0.05; **, P 0.01, ***, P 0.001) represent differences that are statistically significant by the Mann-Whitney test. C57BL/6 mice were infected subcutaneously with 10 3 PFU of Vero cell-derived WNV KUN or WNV NY99 and monitored for survival. Consistent with previous studies, wild-type mice infected with WNV NY99 exhibited an 60% survival rate (Fig. 2A) (5). In contrast, infection with WNV KUN resulted in no appreciable morbidity or mortality (Fig. 2B). Viral burden analysis of spleen and serum samples from wild-type mice at several time points after infection confirmed the attenuated phenotype of WNV KUN compared to that of WNV NY99 (Fig. 3A and E). Analogous to previous studies (7, 21), IFN- R / or IRF-3 / IRF-7 / mice infected with WNV NY99 showed a 100% mortality rate with accelerated kinetics (mean time to death [MTD] of 3.4 0.5 days [n 9 mice] and 5.8 0.4 days ([n 10], respectively). Remarkably, infection of IFN- R / or IRF-3 / IRF-7 / mice with WNV KUN resulted in a 100% mortality rate with only a slight delay in kinetics (MTD of 5.0 0.4 days [n 12] and 6.7 0.5 days [n 11], respectively) (Fig. 2B). Consistent with this result, viral titers from IRF-3 / IRF-7 / mice infected with WNV KUN were markedly greater in all organs tested than those for wild-type mice, although in the brain, they did not reach those observed with WNV NY99 (Fig. 3D, H, and L). In comparison, infection of IRF-7 / mice, which have a blunted systemic IFN- response (6, 11), showed partial restoration of WNV KUN virulence, with an 47% mortality rate compared to 100% mortality after infection with WNV NY99 and delayed kinetics of death (MTD of dying animals, 11.0 1.3 days [n 15]) (Fig. 2B). Replication of WNV KUN was
VOL. 85, 2011 NOTES 5667 FIG. 4. Replication of WNV KUN and WNV NY99 in wild type, IRF-3 /, IRF-7 /, IRF-3 / IRF-7 /, and IFN- R / cells. MEF or macrophages were generated as previously described (7) and infected with WNV KUN or WNV NY99 (MOI of 0.01), and virus production was evaluated by plaque assay at the indicated times for MEF or 24 h after infection for macrophages. Values are averages from triplicate samples generated for three independent experiments. Error bars indicate the standard error of the mean, dashed lines denote the limit of sensitivity, and asterisks ( *, P 0.05; **, P 0.01; ***, P 0.001) represent differences that are statistically significant by an unpaired t test. enhanced in tissues from IRF-7 / mice but also did not attain the levels in the brain observed for WNV NY99 -infected IRF- 7 / mice. For example, although levels of WNV KUN were similar to those of WNV NY99 in the serum and spleen samples (Fig. 3C and G), the amount in the brain was 25- to 60-fold lower on days 4 and 8 after infection (Fig. 3K). This difference is likely because cells from IRF-7 / mice still have an intact IFN- response (6), which could limit WNV KUN virulence in a tissue-specific manner. A deficiency of IRF-3, which by itself does not affect WNV-induced production of type I IFN in some cells or in vivo (4, 5), did not restore WNV KUN virulence, as 93% (n 15) of IRF-3 / mice still survived infection. This compares with a 0% survival rate (n 5) after infection with WNV NY99, as observed previously (5). Somewhat surprisingly, viral titers for the serum and spleen samples from IRF-3 / mice infected with WNV KUN and WNV NY99 were comparable (Fig. 3B and F), although levels in the brain at day 10 were 400-fold lower in IRF-3 / animals infected with WNV KUN (Fig. 3J), which likely explains the mortality results. Thus, IRF-3 had a differential and tissue-specific effect on the control of WNV NY99 and WNV KUN in the brain. Since the attenuation of WNV KUN in vivo correlated with the integrity of key regulatory components of the type I IFN response, we evaluated whether WNV KUN and WNV NY99 replicated differently in primary cells, which produce and respond to type I IFN after WNV infection (6), and compared this to growth curves for congenic IRF-3 /, IRF-7 /, IRF-3 / IRF-7 / or IFN- R / cells. In wild-type murine embryonic fibroblasts (MEF), multistep viral growth curves confirmed that WNV KUN replication was attenuated compared to that for WNV NY99 ( 10- to 80-fold decrease at 24 to 72 h postinfection; P 0.05) (Fig. 4A). Similarly, WNV KUN was attenuated (15- to 80-fold at 24 to 72 h postinfection; P 0.05) in IRF- 3 / or IRF-7 / MEF (Fig. 4B and C), which retain the capacity to produce IFN- or - after WNV infection (5, 6). WNV KUN still replicated less efficiently than WNV NY99 in IRF-3 / IRF-7 / or IFN- R / MEF, which are either virtually or completely deficient in type I IFN signaling (7) (Fig. 4D and E). Thus, in MEF, a loss of the ability to produce or respond to type I IFN augments but does not restore the infectivity of WNV KUN to the levels observed with WNV NY99. This phenotype could be explained by differential expression of antiviral IFN-stimulated genes (ISGs) in each of the deficient cells, some of which are induced differentially by IFN-depen-
5668 NOTES J. VIROL. dent or IRF-3-dependent pathways (9). When we examined infection at 24 h in a second primary cell type, bone marrowderived macrophages, we observed a similar phenotype: a complete loss of type I IFN signaling enhanced WNV KUN infectivity but not to the levels (4-fold lower; P 0.01) observed with WNV NY99 (Fig. 4F). One apparent difference in macrophages was the relatively poor replication of WNV KUN in IRF-3 / IRF-7 / macrophages, which may be due to residual production of IFN- in these cells after WNV infection through an IRF-3- and IRF-7-independent pathway (7). The experiments here establish that mice unable to produce or respond to type I IFN were vulnerable to infection with WNV KUN and suggest that the relative lack of pathogenicity of this natural virus variant in wild-type mice or, possibly, humans can be attributed, in part, to its rapid control by the host type I IFN response. Data obtained ex vivo using genetically deficient primary fibroblasts showed that an absence of the type I IFN enhanced WNV KUN viral replication but not to the level of WNV NY99 ; this correlated with a viral burden analysis of mice, which showed increased WNV KUN infectivity in genetically deficient animals that approached but was not equivalent to that for WNV NY99. One explanation of this discrepancy could be that subsets of cells and tissues differentially express ISGs through IFN-dependent and -independent (yet IRF-3- dependent) pathways (5). Although the genetic basis of the relative attenuation of WNV KUN remains a topic of further study, the phenotype is at least partially due to a reduced ability to antagonize IFN signaling and/or the antiviral activity of specific ISGs. Amino acid substitutions between both viruses are dispersed throughout the genome, with differences in the viral proteins NS1, NS2A, NS2B, NS4A, NS4B, and E of WNV NY99 and WNV KUN identified as possible antagonists in IFN production or signaling (1, 15 19, 24). Recently, WNV NY99 but not WNV KUN NS5 has been identified as a potent inhibitor of IFN-dependent JAK-STAT signaling; remarkably, a single-amino-acid substitution in WNV KUN NS5 restored the inhibitory activity to that observed for WNV NY99 NS5 (15). Nonetheless, the exact contribution of each viral protein in inhibiting the host response in vivo and the identification of the specific molecular determinants that explain differential pathogenesis warrant further studies. NIH grants U19 AI083019 (M.S.D), R01 AI074973 (M.S.D.), and UO1 AI066321 (A.A.K) and Australian NHMRC grant 511129 (A.A.K) supported this work. H.M.L was supported by an NIH Institutional training grant (T32-AI007172). The authors report no conflict of interest. REFERENCES 1. Arjona, A., et al. 2007. West Nile virus envelope protein inhibits dsrnainduced innate immune responses. J. Immunol. 179:8403 8409. 2. Beasley, D. W., L. Li, M. T. Suderman, and A. D. Barrett. 2002. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 296:17 23. 3. Beasley, D. W., et al. 2005. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J. Virol. 79:8339 8347. 4. Bourne, N., et al. 2007. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J. Virol. 81:9100 9108. 5. Daffis, S., M. A. Samuel, B. C. Keller, M. Gale, Jr., and M. S. Diamond. 2007. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and independent mechanisms. PLoS Pathog. 3:e106. 6. Daffis, S., et al. 2008. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J. Virol. 82:8465 8475. 7. Daffis, S., M. S. Suthar, K. J. Szretter, M. Gale, Jr., and M. S. Diamond. 2009. Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog. 5:e1000607. 8. Diamond, M. S. 2009. Mechanisms of evasion of the type I interferon antiviral response by flaviviruses. J. Interferon Cytokine Res. 29:521 530. 9. Grandvaux, N., et al. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferonstimulated genes. J. Virol. 76:5532 5539. 10. Hall, R. A., A. K. Broom, D. W. Smith, and J. S. Mackenzie. 2002. The ecology and epidemiology of Kunjin virus. Curr. Top. Microbiol. Immunol. 267:253 269. 11. Honda, K., et al. 2005. IRF-7 is the master regulator of type-i interferondependent immune responses. Nature 434:772 777. 12. Keller, B. C., et al. 2006. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J. Virol. 80:9424 9434. 13. Khromykh, A. A., M. T. Kenney, and E. G. Westaway. 1998. trans-complementation of flavivirus RNA polymerase gene NS5 by using Kunjin virus replicon-expressing BHK cells. J. Virol. 72:7270 7279. 14. Lanciotti, R. S., et al. 2002. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298:96 105. 15. Laurent-Rolle, M., et al. 2010. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK- STAT signaling. J. Virol. 84:3503 3515. 16. Liu, W. J., H. B. Chen, X. J. Wang, H. Huang, and A. A. Khromykh. 2004. Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J. Virol. 78:12225 12235. 17. Liu, W. J., et al. 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J. Virol. 80:2396 2404. 18. Liu, W. J., et al. 2005. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79:1934 1942. 19. Muñoz-Jordán, J. L., et al. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79:8004 8013. 20. Petersen, L. R., A. A. Marfin, and D. J. Gubler. 2003. West Nile virus. JAMA 290:524 528. 21. Samuel, M. A., and M. S. Diamond. 2005. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79:13350 13361. 22. Scherret, J. H., J. S. Mackenzie, A. A. Khromykh, and R. A. Hall. 2001. Biological significance of glycosylation of the envelope protein of Kunjin virus. Ann. N. Y. Acad. Sci. 951:361 363. 23. Scherret, J. H., et al. 2001. The relationships between West Nile and Kunjin viruses. Emerg. Infect. Dis. 7:697 705. 24. Wilson, J. R., P. F. de Sessions, M. A. Leon, and F. Scholle. 2008. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J. Virol. 82:8262 8271.